Day 1 :
Keynote Forum
Ashraf H Abadi
German University in Cairo, Egypt
Keynote: Discovery of extremely potent and pan-genotypic anti-hepatitis C virus
Time : 10:00-11.00
Biography:
Abstract:
Although of the success of Direct Acting Antivirals (DAAs) in the treatment of Hepatitis C Virus (HCV) there is still a room for further research and development aiming to: Discovery of more potent pan-genotypic DAA to reduce the duration of treatment, discovery of DAA with high threshold to develop resistance to allow mono therapy and not to lose the therapeutic action throughout the treatment period, expand the genotypic coverage to include GT3 which was found to be one of the hardest to treat genotypes using DAA and to develop safer DAA suitable for the treatment of HCV in children. This study describes novel small molecules that inhibit the growth of HCV in replicon assays. Several compounds showed median Effective Concentration (EC50s) in the low picomolar range and were of median cytotoxicity CC50s in the micromolar range, leading to median selectivity indices more than six orders of magnitude, which indicate their safety. Several compounds were more active than the clinically used candidate Dacaltasvir against several genotypes including GT1b, GT3 and GT4 and with lower tendency to develop resistance even after 15 weeks of continuous treatment.
Keynote Forum
M.S. Ashawat
Laureate Institute of Pharmacy, India
Keynote: An Easy Understanding Of Novel Herbal Cosmetic Approaches
Time : 11:20-12:20
Biography:
Abstract:
- Pharmacotherapy|Nanotechnology|Biopharmaceutics|Pharmacovigilance| Drug Development|Toxicology
Session Introduction
Jeremy Choo
Republic Polytechnic, Singapore
Title: Design, develop and evaluate dispensary software in RP-KTPH teaching dispensary
Biography:
Abstract:
Tariq Dennison
GFM Asset Management, Hong Kong
Title: A Fund Manager’s Investment Outlook on the Biotechnology and Pharmaceutical Sectors
Biography:
Tariq Dennison CFPCM manages retirement plan investment portfolios at his own firm GFM Asset Management, a Hong Kong licensed asset manager and US registered investment advisor. Mr. Dennison is the author of the book “Invest Outside the Box: Understanding Different Asset Classes and Strategies”, and puts this into practice by investing client accounts in portfolios of stocks, bonds, and ETFs the same way he invests his own money. Tariq has worked at Commerzbank, Bear Stearns, JP Morgan, CIBC, and Society General in New York, Toronto, London and Hong Kong, and also teaches fixed income and alternative assets at ESSEC Business School in Singapore and for CFA Singapore. Mr. Dennison holds a Masters in Financial Engineering degree from the University of California at Berkeley’s Haas School of Business. Tariq is one of the few Hong Kong based specialists in US pension funds, including IRA, 401(k), and defined benefit plans
Abstract:
Statement of the Problem: Biotechnology and pharmaceutical stocks have significantly outperformed broader equity benchmarks over the past 10 years, but these companies remain uniquely difficult to value and risk manages, even for professional investors. Fund Manager Tariq Dennison presents a financial outlook of stocks in the biotechnology and pharmaceutical sectors, starting with a top-down look at how broad and industry focused funds and ETFs choose to invest in these sectors, using examples from actual funds. Next, a few examples of financial models of select companies are highlighted to show some of the challenges and opportunities in valuing shares of companies focused on different stages of drug development. Research and early development stage companies are more often valued and risk managed using a “real options” model, while later stage companies with mature cash flows may be valued with classic “discounted cash flow” models. These top-down and bottom up views are then combined to pave an outlook for investing in funds and shares in the bio & pharma space, and what factors might change fund managers’ views. Valuation is a key emphasis of this presentation and main difference between a practitioner and investor in technologies, since it is easy to lose money investing in even the best technologies if the price paid is too high.
Ashraf H Abadi
German University in Cairo, Egypt
Title: Modulation of the estrogenic/antiestrogenic properties of the anticancer drug Tamoxifen
Biography:
Abstract:
Pravin Kumar
Atopic Dermatitis: Etiology and Treatment, India
Title: Atopic Dermatitis: Etiology and Treatment
Biography:
Mr. Pravin Kumar is presently working as Associate Professor in Department of Pharmaceutics, Laureate Institute of Pharmacy, Kangra, Himachal Pradesh, India. Completed his post- graduation in 2008 from JSS College of Pharmacy, Mysore, India and currently pursuing his Ph.D from Uttarakhand Technical University, Dehradun, India. Pharmaceutical researcher and teacher with Master in Pharmacy (Industrial Pharmacy) and Bachelor in Pharmacy, degree in pharmaceutical sciences with more than 10 years of total experience. Guided more than 15 post graduate students in pharmaceutical sciences related research. Basic focused area in research is about the herbal excipients and drugs in pharmaceutical sciences. Presently, doing research on the development of topical formulation of herbal drugs for the long-term management of atopic dermatitis. More than 16 internationals research and review publications with total impact factor of 5.012. Participated as speaker and research delegate in more than 10 international and national conferences.
Abstract:
Atopic Dermatitis: Etiology and Treatment
- Poster
Session Introduction
Karina Grzanka
Poznan University of Medical Sciences, Poland
Title: The system of tolfenamic acid with cyclodextrins and their identification
Biography:
Abstract:
The studies were supported by Ministry of Science and Higher Education from project “ Best of The Best 3.0”
Delfina Hanus
Poznań University of Medical Sciences, Poland